Du är här


Swedish Orphan Biovitrum AB (publ): Resolutions from Sobi's AGM

The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General meeting (AGM)
convened earlier today in Stockholm and voted in favour of the resolutions
proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of

The AGM adopted the income statements and the balance sheets and approved the
proposal to carry forward the retained profits of SEK 4,672,982,798.

The board members and the chief executive officer were discharged from
liability for the financial year 2013.

Election of Board of Directors, remuneration to the Directors and election of

The ordinary board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen,
Lennart Johansson, Helena Saxon, Hans GCP Schikan and Hans Wigzell were
re-elected to the Board. Annette Clancy was elected as new board member. Bo
Jesper Hansen was re-elected chairman of the Board.

The AGM approved the compensation to the Board in accordance with the
nomination committee's proposal.

Ernst&Young was elected as new auditor of Sobi until the end of the annual
general meeting 2015.

Principles for remuneration for the management, long-term incentive program
and transfer of own shares

The AGM approved the proposed guidelines for remuneration for the management.

The AGM also approved the Board's proposal regarding the implementation of a
long-term incentive program, and hedging arrangements in respect of the
program including a directed issue of no more than 396,180 series C shares,
authorisation for the Board to decide on a repurchase of all issued series C
shares and transfers of no more than 1,100,235 own common shares to program

The Board's proposal regarding transfer of no more than 338,766 own common
shares on the stock exchange for the purpose of covering certain payments,
mainly social security contributions, that may occur in relation to the Share
Program 2011 and the CEO Share Program 2011, was also approved by the AGM.

For full details on each proposal adopted by the AGM please refer to


About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of
specialty and rare disease products for partner companies. Sobi is a pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

|Media relations Investor relations |
|Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
|T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
|oskar.bosson@sobi.com jorgen.winroth@sobi.com |
| |
The information was released for public distribution on May 8, 2014 at 18:30

Resolutions from Sobi's AGM


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.